Clinical Trial Update: Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression [Phase 4]

View source ↗

Summary

This document reports a Phase 4 clinical trial evaluating desipramine for improving cellular signaling and reducing symptoms in major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Desipramine (desipramine)

Snippet

Sponsor: Harvard Medical School (HMS and HSDM) | Conditions: Depression | Phase 4 | Status: COMPLETED